Clinical trial
Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D
NCT05847413 is registered in ClinicalTrials.gov with Benaroya Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D
- Lead sponsor
- Benaroya Research Institute
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 30, 2020
- Completion date
- December 10, 2021
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
type 1 diabetes